SILVER SPRING, Md., Aug. 22, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of August 22, 2011.
(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)
FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.
Meetings, Workshops and Congressional Testimony:
Wednesday, 8/24 The Center for Tobacco Products holds its sixth Stakeholder Discussion Series session with distributors, importers, retailers, and wholesalers. 8:45 a.m. CDT, Dallas Marriott City Center, 650 North Pearl St., Dallas.
Press Office Contact: Jeffrey Ventura, 301-796-2807, jeffrey.ventura@fda.hhs.gov
Thursday, 8/25 Generic Drug User Fee Public Meeting to update and gather additional comments on development of a generic drug user fee. 2 p.m., 10903 New Hampshire Ave., Building 1, Room 4101, Silver Spring, Md. Advance registration recommended to GDUFA_Meeting3@fda.hhs.gov
Press Office Contact: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Tuesday, 8/30 The General and Plastic Surgery Devices Panel will discuss and make recommendations on postmarketing issues related to silicone gel-filled breast implants during a two-day meeting. 8 a.m., Hilton Washington D.C. North/Gaithersburg, 620 Perry Pkwy., Ballroom, Gaithersburg, Md.
Press Office Contact: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
On the Web:
Communicating Risks and Benefits: An Evidence-Based User’s Guide
Provides the scientific foundations for effective communication.
Press Office Contact: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov
515 Program Initiative Project Status Update: Female Condom, Pacemaker Repair or Replacement Material, Ventricular Bypass (Assist) Device
Press Office Contact: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov
Draft Guidance for Industry and Food and Drug Administration Staff - Postmarket Surveillance Under Section 522 of the Federal Food, Drug and Cosmetic Act
Press Office Contact: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov
FDA Office of Public Affairs Contact Information:
Call or email FDA Office of Public Affairs, 301-796-4540, fdaopa@fda.hhs.gov
List of FDA press officers and beats
More Resources:
FDA News and Events
FDA Photos (Flickr)
Consumer Health Information
SOURCE U.S. Food and Drug Administration
